A report from the international consensus on diagnosing and treating the infected diabetic foot

Diabetes/Metabolism Research and Reviews

Volumn 20, Issue SUPPL. 1, 2004, Pages

  Lipsky, Benjamin A ^a  

^a VA Puget Sound   (United States)

Author keywords

Antibiotic therapy; Diabetic foot infections; Foot complications; Guidelines; Osteomyelitis; Wound cultures

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTIZOXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; DICLOXACILLIN; FUSIDIC ACID; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MECILLINAM; NAFCILLIN; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PRISTINAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANATOMY; ARTERY PERFUSION; ARTICLE; BONE INFECTION; DIABETIC FOOT; DISEASE PREDISPOSITION; DRUG TISSUE LEVEL; FOOT AMPUTATION; GANGRENE; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFECTIOUS ARTHRITIS; INFLAMMATION; MICROORGANISM; MYOSITIS; NEUROPATHY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SKIN INJURY; SUBCUTANEOUS TISSUE; TISSUE INJURY;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DIABETIC FOOT; HUMANS; INFECTION; OSTEOMYELITIS; WOUND HEALING;

EID: 2642583933     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.453     Document Type: Article

References (64)

1. Lipsky BA. Infectious problems of the foot in diabetic patients. In The Diabetic Foot (6th edn), Bowker JH, Pfeifer MA (eds). Mosby: St. Louis, 2001; 467-480.
2. International Working Group on the Diabetic Foot. International Consensus on the Diabetic Foot. Amsterdam, 1999; 1-96.
3. Pecoraro RE, Ahroni JH, Boyko EJ, Stencil VL. Chronology and determinants of tissue repair in diabetic lower-extremity ulcers. Diabetes 1991; 40: 1305-1313.
4. Reiber GE, Pecoraro RE, Koepsell TD. Risk factors for amputation in patients with diabetes mellitus. A case control study. Ann Intern Med 1992; 117: 97-105.
5. Wilson RM. Neutrophil function in diabetes. Diabet Med 1986; 6: 509-512.
6. McMahon MM, Bistrian BR. Host defenses and susceptibility to infection in patients with diabetes mellitus. Infect Dis Clin North Am 1995; 9: 1-10.
7. Sentochnik DE, Eliopoulos GM. Infection and diabetes. In Joslin's Diabetes Mellitus (13th edn), Kahn CR, Weir GC (eds). Lea & Febiger: Philadelphia, 1994; 867-868.
8. Bridges RM, Deitch EA. Diabetic foot infections. Pathophysiology and treatment. Surg Clin North Am 1994; 74: 537-545.
9. American Diabetes Association. Consensus development conference on diabetic foot wound care. Diabetes Care 1999; 22: 1354-1360.
10. Eneroth M, Apelqvist J, Stenstrom A. Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. Foot Ankle Int 1997; 18: 716-722.
11. Edelson GW, Armstrong DG, Lavery LA, Caicco G. The acutely infected diabetic foot is not adequately evaluated in an inpatient setting. Arch Intern Med 1996; 156: 2373-2378.
12. Armstrong DG, Perales TA, Murff RT, Edelson GW, Welchon JG. Value of white blood cell count with differential in the acute diabetic foot infection. J Am Podiatr Med Assoc 1996; 86: 224-227.
13. Lipsky BA, Pecoraro RE, Wheat JL. The diabetic foot: soft tissue and bone infection. Infect Dis Clin North Am 1990; 4: 409-432.
14. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998; 21: 855-859.
15. Get R. Newer concepts in the surgical management of lesions of the foot in the patient with diabetes. Surg Gynecol Obstet 1984; 158: 213-215.
16. Lipsky BA, Pecoraro RE, Larson SA, Ahroni JH. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch Intern Med 1990; 150: 790-797.
17. Wheat LJ, Allen SD, Henry M, et al. Diabetic foot infections. Bacteriologic analysis. Arch Intern Med 1986; 146: 1935-1940.
18. Pellizzer G, Strazzabosco M, Presi S, et al. Deep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet Med 2001; 18: 822-827.
19. Gerding DN. Foot infections in diabetic patients: the role of anaerobes. Clin Infect Dis 1995; 20(Suppl. 2): S283-S288.
20. Tentolouris N, Jude EB, Smirnof I, Knowles EA, Boulton AJM. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med 1999; 16: 767-771.
21. Wagner AH, Reike H, Angelkort B. Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections. Dtsch Med Wochenschr 2001; 126: 1353-1356.
22. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis 1997; 25: 1318-1326.
23. Wrobel JS, Connolly JE. Making the diagnosis of osteomyelitis. The role of prevalence. J Am Podiatr Med Assoc 1998; 88: 337-343.
24. Jones V. Debridement of diabetic foot lesions. The Diabetic Foot 1998; 3: 88-94.
25. Jaegeblad G, Apelqvist J, Nyberg P, Berger B. The diabetic foot: from ulcer to multidisciplinary team approach. A process analysis. Abstracts of the 3rd International Symposium of The Diabetic Foot, Noordwijkerhout: The Netherlands, May 6, 1998; Abstract p87, 149.
26. Robson MC, Mannari RJ, Smith PD, Payne WG. Maintenance of wound bacterial balance. Am J Surg 1999; 178: 399-402.
27. O'Meara SM, Cullum NA, Majid M, Sheldon TA. Systemic review of antimicrobial agents used for chronic wounds. Br J Surg 2001; 88: 4-21.
28. Chantelau E, Tanudjaja T, Altenhöfer F, Ersanli Z, Lacigova S, Metzger C. Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabet Med 1996; 13: 156-159.
29. Hirschl M, Hirschl AM. Bacterial flora in mal perforant and antimicrobial treatment with ceftriaxone. Chemotherapy 1992; 38: 275-280.
30. Foster AVM, Bates M, Doxford M, Edmonds ME. Should oral antibiotics be given to "clean" foot ulcers with no cellulitis? Abstracts of the 3rd International Symposium of The Diabetic Foot, Noordwijkerhout: The Netherlands, May 6, 1998; Abstract O13.
31. Kuck EM, Bouter KP, Hoekstra JBL, Conemans JMH, Diepersloot RJA. Tissue concentrations after a single-dose, orally administered ofloxacin in patients with diabetic foot infections. Foot Ankle Int 1998; 19: 38-40.
32. Muller M, Brunner M, Hollenstein U, et al. Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob Agents Chemother 1999; 43: 2056-2058.
33. Marangos MN, Skoutelis AT, Nightengale CH, et al. Absorption of ciprofloxacin in patients with diabetic gastroparesis. Antimicrob Agents Chemother 1995; 39: 2161-2163.
34. Raymakers JT, Houben AJ, vd Heyden JJ, Tordoir JH, Kitslaar PJ, Schaper NC. The effect of diabetes and severe ischaemia on the penetration of ceftazidime into tissues of the limb. Diabet Med 2001; 18: 229-234.
35. el-Sarkey Mel-S. Local intravenous therapy in chronic inflammatory and vascular disorders of the foot. Int Surg 1997; 82: 175-181.
36. de Lalla F, Novelli A, Pellizzer G, et al. Regional and systemic prophylaxis with teicoplanin in monolateral and bilateral total knee replacement procedures: study of pharmacokinetics and tissue penetration. Antimicrob Agents Chemother 1993; 37: 2693-2698.
37. Dorigo B, Cameli AM, Trapani M, Raspanti D, Torri M, Mosconi G. Efficacy of femoral intra-arterial administration of teicoplanin in gram-positive diabetic foot infections. Angiology 1995; 46: 1115-1122.
38. Connolly JE, Wrobel JS, Anderson RF. Primary closure of infected diabetic foot wounds. A report of closed instillation in 30 cases. J Am Podiatr Med Assoc 2000; 90: 175-182.
39. Lipsky BA, McDonald D, Litka PA. Treatment of infected diabetic foot ulcers: topical MSI-78 vs. oral ofloxacin (abstract). Diabetologia 1997; 40(Suppl. 1): 482.
40. O'Meara S, Cullum N, Majid M, Sheldon T. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technol Assess 2000; 4: 1-237.
41. Roeder B, Van Gils CC, Maling S. Antibiotic beads in the treatment of diabetic pedal osteomyelitis. J Foot Ankle Surg 2000; 39: 124-130.
42. Yamashita Y, Uchida A, Yamakawa T, Shinto Y, Araki N, Kato K. Treatment of chronic osteomyelitis using calcium hydroxyapatite ceramic implants impregnated with antibiotics. Int Orthop (SICOT) 1998; 22: 247-251.
43. Kollenberg LO. A new topical antibiotic delivery system. World Wide Wounds 1998; 1: 1-19. http://www.worldwidewounds.com/1998/july/ Topical-Antibiotic-Delivery-System/topical
44. Lipsky BA. Evidence-based antibiotic therapy of diabetic foot infections. FEMS Immunol Med Microbiol 1999; 26: 267-276.
45. Cunha BA. Antibiotic selection for diabetic foot infections: a review. J Foot Ankle Surg 2000; 39: 253-257.
46. Ragnarson Tennvall G, Apelqvist J, Eneroth M. Costs of deep foot infections in patients with diabetes mellitus. PharmacoEcconomics 2000; 18: 225-238.
47. McKinnon PS, Paladino JA, Grayson ML, Gibbons GW, Karchmer AW. Cost effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1997; 24: 57-63.
48. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parental-to-oral regimens. Clin Infect Dis 1997; 24: 643-648.
49. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994; 18: 683-693.
50. Venkatesan P, Lawn S, Macfarlane RM, Fletcher EM, Finch RG, Jeffcoate WJ. Conservative management of osteomyelitis in the feet of diabetic patients. Diabet Med 1997; 14: 487-490.
51. Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD. Outcome of diabetic foot infections treated conservatively. A retrospective cohort study with long-term follow-up. Arch Intern Med 1999; 159: 851-856.
52. Senneville E, Yazdanpanah Y, Cazaubiel M, et al. Rifampicinofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother 2001; 48: 927-930.
53. Gough A, Clapperton M, Rolando N, Foster AVM, Philpott-Howard J, Edmonds ME. Randomized placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infections. Lancet 1997; 350: 855-859.
54. de Lalla F, Pellizzer G, Strazzabosco M, et al. Randomized prospective controlled trial of recombinant granulocyte-colony stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother 2001; 45: 1094-1098.
55. Yonem A, Cakir B, Guler S, Azal OO, Corakci A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab 2001; 3: 332-337.
56. Kaestenbauer T, Hoernlein B, Sokol G, Irsigler K. Evaluation of ranulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers. Diabetologia 2002; 46: 27-30.
57. Peck KR, Son DW, Song J-H, Kim S, Oh M-D, Choe KW. Enhanced neutrophil functions by recombinant human granulocyte colony-stimulating factor in diabetic patients with foot infections in vitro. J Korean Med Sci 2001; 16: 39-44.
58. Stone JA, Cianci P. The adjunctive role of hyperbaric oxygen in the treatment of lower extremity wounds in patients with diabetes. Diab Spectrum 1997; 10: 118-123.
59. Wunderlich RP, Peters EJG, Lavery L. Systemic hyperbaric oxygen therapy. Lower-extremity wound healing and the diabetic foot. Diabetes Care 2000; 23: 1551-1555.
60. Lee SS, Chen C-Y, Chan Y-S, Yen C-Y, Chao E-K, Ueng SW-N. Hyperbaric oxygen in the treatment of diabetic foot infection. Chang Gung Med J 1997; 20: 17-22.
61. Bakker DJ. Hyperbaric oxygen therapy and the diabetic foot. Diabetes Metab Res Rev 2000; 16(Suppl. 1): S58-S62.
62. Armstrong DG, Nguyen HC. Improvement in healing with aggressive edema reduction after debridement of foot infection in persons with diabetes. Arch Surg 2000; 135: 1405-1409.
63. Eneroth M, Larsson J, Apelqvist J. Deep foot infection in diabetes mellitus - an entity with different characteristics, treatment and prognosis. J Diabetes Complications 1999; 13(5-6): 254-263.
64. Hauser CJ. Tissue salvage by mapping of skin surface transcutaneous oxygen tension index. Arch Surg 1987; 122: 1128-1130.